Treating metastatic breast cancer with metronomic VEX in the METEORA-II trial

Unanswered questions in the METEORA-II trialПодробнее

METEORA-II: metronomic VEX versus paclitaxel in ER+/HER2- metastatic breast cancerПодробнее

Using metronomic chemotherapy as a second-line treatment in head and neck cancerПодробнее

Advantages of metronomic chemotherapy in ER+/HER2- metastatic breast cancerПодробнее

NCI Minute: Immunotherapy for Metastatic Breast CancerПодробнее

ICON: chemotherapy combined with ipilimumab and nivolumab in metastatic HR+ breast cancerПодробнее

Treatment strategies for HER2+ metastatic breast cancerПодробнее

monarcHER: final OS results of abemaciclib in HR+, HER+ breast cancerПодробнее

Metronomic chemotherapy in Breast Cancer : We are onПодробнее

Clinical applications of liquid biopsy in metastatic breast cancerПодробнее

Exploring Abemaciclib for the Treatment of Brain Metastases in HR+/HER2- Breast CancerПодробнее

Management of premenopausal HR+/HER2- breast cancer with micro-metastasisПодробнее

Therapeutic landscape for patients with HER2-positive breast cancer with active brain metastasesПодробнее

Therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancerПодробнее

Treatment for Metastatic Breast CancerПодробнее

Decision-making in metastatic HER2+ breast cancerПодробнее

Is there treatment for metastatic breast cancer?Подробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

Developing novel guidelines for breast cancer with lymph node micro-metastasisПодробнее